Sage open pediatrics · 2026
Efficacy of Oral Arginine as Treatment to Improve Height in Prepubertal Children With Idiopathic Short Stature: A Systematic Review and Meta-Analysis.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Virú-Loza Manuel André, Chávez-Nomberto Ruth Elizabeth, Hernandez Adrian V
Аннотация
BACKGROUND: Arginine can stimulate growth hormone production. However, a synthesis of the evidence on the effect in children's height is lacking.
OBJECTIVES: To systematically evaluate the efficacy of oral arginine in improving height in prepubertal children with idiopathic short stature.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES AND METHODS: We included clinical trials and cohort studies. We searched in 7 databases until May 31, 2025. Effects were pooled using standardized mean differences (SMDs) and re-expressed as mean differences (MDs).
RESULTS: We only found low-quality studies. Oral arginine administered for 6 or 12 months increased growth velocity (SMD 0.66, 95% CI 0.21-1.12), but the benefit was clinically small (re-expressed MD 0.59 cm/year [95% CI 0.19-1.00]), and the effect was not statistically significant when administered for exclusively 12 months.
CONCLUSION: Oral arginine administered for 12 months may not affect growth. Well-designed RCTs are required.
REGISTRATION: PROSPERO (CRD42024503778).
OBJECTIVES: To systematically evaluate the efficacy of oral arginine in improving height in prepubertal children with idiopathic short stature.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES AND METHODS: We included clinical trials and cohort studies. We searched in 7 databases until May 31, 2025. Effects were pooled using standardized mean differences (SMDs) and re-expressed as mean differences (MDs).
RESULTS: We only found low-quality studies. Oral arginine administered for 6 or 12 months increased growth velocity (SMD 0.66, 95% CI 0.21-1.12), but the benefit was clinically small (re-expressed MD 0.59 cm/year [95% CI 0.19-1.00]), and the effect was not statistically significant when administered for exclusively 12 months.
CONCLUSION: Oral arginine administered for 12 months may not affect growth. Well-designed RCTs are required.
REGISTRATION: PROSPERO (CRD42024503778).